Currently, the only retrospective study with a small sample size (14 patients) first confirmed the CNS response to dacomitinib, with an encouraging iORR of 85.7% and iDCR of 100% in patients with EGFR‐mutated NSCLC.13 Here, EGFR is linked to non-small cell lung carcinoma.